📥  FREE DOWNLOAD

For research professionals only — instant download, no payment required

What Is BPC-157? Structure, Sequence, Research Evidence and UK Supplier Checks

What is BPC-157? BPC-157, also known as Body Protection Compound 157, is a synthetic 15-amino acid pentadecapeptide derived from a partial sequence of the human gastric protective protein. Published research on it comes mainly from animal (largely rat) models, with a smaller number of cell-culture studies, covering angiogenesis pathways, fibroblast biology, growth factor interactions and gastrointestinal models. Human evidence is very limited.  

This guide sets out exactly what BPC-157 is at the structural and mechanistic level, what it has been investigated for in published laboratory research and how to source BPC-157 in the UK with full documentation transparency.

BPC-157 is supplied for in-vitro laboratory research only. It is not a licensed medicinal product under the UK Human Medicines Regulations 2012, and no dosing or administration guidelines are provided in this guide or in any Ascend Peptides UK documentation. 

The compound is supplied to qualified research professionals (laboratories, academic institutions, research scientists) for cellular and tissue research model applications. Tested batches of BPC-157 are independently analysed by Janoshik, with a batch-specific Certificate of Analysis stating measured content and purity.

📥  FREE DOWNLOAD

For research professionals only — instant download, no payment required

What is BPC-157? Ascend Peptides UK BPC-157 10mg research peptide vial
What Is BPC-157? Complete Research Peptide Guide for UK Laboratory Research

What Is BPC-157 at the Molecular Level?

BPC-157 is a synthetic 15-amino acid peptide (a pentadecapeptide) corresponding to a partial sequence of the human gastric protective protein. 

The compound is supplied to laboratories as a lyophilised (freeze-dried) white powder for reconstitution before in vitro research use. The molecular structure and basic chemistry of BPC-157 are documented below.[1]

Molecular Property

Value

Compound name

BPC-157 (Body Protection Compound 157)

Peptide class

Pentadecapeptide (15 amino acid sequence)

Amino acid sequence

Gly Glu Pro Pro Pro Gly Lys Pro Ala Asp Asp Ala Gly Leu Val

Molecular formula

C62H98N16O22

Molecular weight

≈ 1419.55 Da

Source structure

Partial sequence of human gastric protective protein

Supplied format

Lyophilised white powder for reconstitution

Storage

See the BPC-157 product page (storage conditions are being confirmed with the manufacturer)

 

Three structural properties define BPC-157 in the research peptide category. First, it is a pentadecapeptide, meaning it contains exactly 15 amino acids, which places it in the medium-length peptide range (longer than tripeptides like GHK-Cu, shorter than full protein fragments like AOD-9604). Second, it is derived from a partial sequence of the human gastric protective protein, which is the origin of the “Body Protection Compound” name. Third, its originating research group has described it as stable in human gastric juice (Sikiric et al., 2011); Ascend does not publish stability data for the supplied material, and storage conditions are being confirmed with the manufacturer.

Tested batches are independently analysed by Janoshik, with a batch-specific Certificate of Analysis stating measured content and purity. The complete laboratory quality control workflow is documented on the how we test peptides page.

How Does BPC-157 Work in Cellular Research Models?

In published in-vitro research literature, BPC-157 has been investigated across several distinct cellular research pathways. 

No specific receptor for BPC-157 has been established. It is studied in different mechanistic contexts from TB-500 (a thymosin beta-4 fragment carrying its actin-binding motif) and GHK-Cu (a copper-binding tripeptide), but published studies combining these compounds are few, so they should not be treated as independent variables in combined designs.

Documented Research Pathways for BPC-157

  • Angiogenic factor expression research, particularly in endothelial cell line models examining vascular endothelial growth factor and related angiogenic markers.

  • Fibroblast biology research, examining fibroblast migration, fibroblast proliferation kinetics, and collagen gene expression in dermal and tendon cell line models.

  • Growth hormone receptor interaction research, including studies of BPC-157 effects on growth hormone receptor expression and downstream signalling in cellular research models.[2]

  • Gastrointestinal cellular research, in line with the origin of BPC-157 as a pentadecapeptide derived from the human gastric protective protein sequence.

  • Nitric oxide pathway research at the cellular level, examining BPC-157 interactions with nitric oxide synthesis and signalling.

Evidence status. Most published BPC-157 research comes from rodent studies, a large share of them from one research group (Sikiric and colleagues, Zagreb), alongside a smaller number of cell-culture studies such as Chang et al. (2011, 2014). A 2025 systematic review in orthopaedic sports medicine identified 35 preclinical studies and one human study (a retrospective series of 12 patients), and found no human safety data (Vasireddi et al., 2025). These findings do not establish safety or benefit in humans. 

The compound is often studied in parallel with TB-500 (a Thymosin Beta 4 fragment), which is studied as a fragment carrying thymosin beta-4’s actin-binding motif. For the complete mechanistic comparison between BPC-157 and TB-500, see the TB-500 vs BPC-157 research peptide comparison guide on the Ascend Peptides UK research blog.

BPC-157 Research Applications in UK Laboratory Research

UK laboratory researchers working with BPC-157 typically apply the compound across four research application areas. The application chosen depends on the specific experimental focus of the research programme. Much of the published evidence in these areas comes from animal models rather than cell culture.

Application 1: Angiogenesis Research in Endothelial Cell Models

Angiogenesis research investigates how new blood vessels form from existing vasculature at the cellular level. BPC-157 has been studied in endothelial cell line models examining vascular endothelial growth factor expression, endothelial cell migration kinetics, and tube formation assays. This application area accounts for a substantial proportion of published BPC-157 research and is one of the principal reasons the compound is included in UK research peptide catalogues.

Application 2: Fibroblast Biology Research in Dermal and Tendon Cell Lines

Fibroblast biology research examines the cellular biology of connective tissue cells, including fibroblast migration, proliferation, and extracellular matrix production. 

BPC-157 has been investigated in dermal fibroblast and tendon fibroblast cell line models, with documented research applications covering collagen gene expression analysis and fibroblast migration assay work. This application area is relevant to broader regenerative biology research at the in-vitro level.

Application 3: Growth Hormone Receptor Interaction Research

Some published research has examined BPC-157 interactions with the growth hormone receptor signalling pathway at the cellular level. 

This research application sits at the intersection of the recovery research category and the GH axis research category, making BPC-157 a relevant compound for laboratories conducting multi pathway research programmes. The Ascend Peptides UK catalogue stocks both BPC-157 and the GH axis research peptides for combined research designs.

Application 4: Gastrointestinal Cellular Research

Given the origin of BPC-157 as a peptide derived from the human gastric protective protein sequence, the compound has been studied in gastrointestinal cellular research models, including gastric epithelial cell line work and intestinal cell line research. 

This application area aligns with the structural origin of the compound and remains an active area of in-vitro literature.

BPC-157 UK Supplier Standards: What to Verify Before Purchase

BPC-157 is commonly discussed as a higher-risk compound for substitution or mislabelling within the research peptide market. The combination of high search demand and structural complexity (15 amino acids, multiple proline residues, distinctive sequence) makes BPC-157 a target for substitution with cheaper compounds that may pass basic visual inspection but fail independent analytical verification. Four documentation standards distinguish a verified UK supplier of BPC-157 from an unverified one. The complete framework is set out on the batch verification page.

Documentation Standard

Industry Norm

Ascend Peptides UK

HPLC purity verification

Self-reported by the supplier

Independent Janoshik analysis, purity stated per tested batch

LC-MS molecular identity

Often not performed

Not separately reported on current Janoshik certificates

Batch-specific Certificate of Analysis

Generic or unavailable

Batch-referenced CoA for the tested sample

UK dispatch standards

3 to 7 working days

Same working-day UK dispatch on in-stock orders before 3pm (Mon–Fri)

 

Tested BPC-157 batches are independently analysed by Janoshik for measured content and purity. The Janoshik Certificate of Analysis is publicly accessible from the CoA archive before the order is placed. 

For the complete research grade standards framework that defines what “research grade” actually means in UK laboratory peptide supply, see the research grade standards page.

Before Ordering BPC-157: Free Research Buyer Starter Pack

The Research Buyer Starter Pack is a free downloadable guide for UK research buyers evaluating peptide suppliers. It converts the documentation framework into a practical buyer checklist covering exactly what to verify before ordering BPC-157 or any other research peptide. 

Run any supplier against the checklist, including Ascend Peptides UK, to confirm the documentation standard before purchase.

BPC-157 Storage Information

Storage conditions for current BPC-157 stock are being confirmed with the manufacturer; the current position is shown on the BPC-157 product page. Lyophilised BPC-157 is supplied in a sealed glass vial. 

Ascend Peptides UK does not publish reconstitution, solvent or in-use instructions; these are decisions for your own validated laboratory protocol. General background on peptide storage is in the peptide storage guide.

What Ascend Currently Publishes About BPC-157 Storage

  • Lyophilised BPC-157: supplied in a sealed vial; storage conditions are being confirmed with the manufacturer.

  • Solvent choice: a decision for your own validated laboratory protocol; Ascend does not specify one.

  • Prepared solutions: Ascend does not publish storage conditions for prepared solutions.

  • In-use period: not published by Ascend Peptides UK.

  • Published literature notes that repeated freeze-thaw cycles can promote peptide aggregation.

BPC-157 in Combined Research Peptide Protocols

Ascend Peptides UK supplies BPC-157 in two bundles: BPC-157 plus TB-500, and BPC-157 plus TB-500 plus GHK-CU. Published studies combining these compounds are few, so the bundles are a supply option, not evidence of combined or additive effects.

Bundle

Compounds Included

Price

Research Application

Regenesis Complex

BPC-157 10mg + TB-500 10mg

See bundle page

Dual compound recovery research protocols

Tri Regenerative Complex

BPC-157 10mg + TB-500 10mg + GHK-CU 100mg

See bundle page

Three compound laboratory research programmes 

Single-supplier sourcing means every compound in the research design comes from one supplier. Single-supplier sourcing does not establish that supplied vials share a verified manufacturing lot; each published certificate identifies the specific sample or batch that was tested. Both the Regenesis Complex and the Tri Regenerative Complex bundles supply the compounds from a single supplier at a bundle price. For the complete recovery research peptide category framework, see the recovery research peptides UK page.

Why UK Researchers Source BPC-157 from Ascend Peptides UK

  • Independent Janoshik testing — measured content and purity reported for each tested batch.
  • Each Janoshik report carries a verification key, so the certificate can be checked directly with the laboratory 
  • Published Certificate of Analysis identifying the tested sample or batch.
  • Same working-day UK dispatch on in-stock orders placed before 3pm, Monday to Friday, via Royal Mail Tracked 24.
  • FREE 10ml bacteriostatic water on orders of £75 or more.
  • Bundles available with TB-500 (Regenesis Complex) and with TB-500 plus GHK-CU (Tri Regenerative Complex); current prices are on each bundle page.
  • Single-supplier sourcing across the recovery research peptide range; this does not establish that supplied vials share a verified manufacturing lot.

What Is BPC-157? Frequently Asked Questions

What does BPC-157 stand for?

BPC-157 stands for Body Protection Compound 157. It is a synthetic 15-amino acid pentadecapeptide derived from a partial sequence of the human gastric protective protein. The compound is supplied for in-vitro laboratory research only.

What is the molecular structure of BPC-157?

BPC-157 is a 15-amino acid pentadecapeptide with the sequence Gly Glu Pro Pro Pro Gly Lys Pro Ala Asp Asp Ala Gly Leu Val. The molecular formula is C62H98N16O22 and the molecular weight is approximately 1419.55 Da.

What is BPC-157 used for in research?

In published in-vitro research literature, BPC-157 has been studied across four principal application areas: angiogenesis research in endothelial cell models, fibroblast biology research in dermal and tendon cell lines, growth hormone receptor interaction research, and gastrointestinal cellular research. Most of this evidence comes from animal (largely rat) models, with a smaller number of cell-culture studies. Human evidence is very limited: a 2025 systematic review found one small retrospective human study and no human safety data, so these findings do not establish safety or benefit in humans.

Is BPC-157 the same as TB-500?

No. BPC-157 and TB-500 are mechanistically distinct compounds. BPC-157 is a 15-amino acid pentadecapeptide derived from gastric protective protein, for which no specific receptor has been established. TB-500 is described as a short synthetic fragment of thymosin beta-4 carrying its actin-binding motif. Published studies combining the two are few, and they should not be treated as independent variables in a combined design. For the complete comparison, see the TB-500 vs BPC-157 research peptide comparison guide.

What is the WADA status of BPC-157?

BPC-157 is listed on the World Anti-Doping Agency (WADA) Prohibited List under category S0, Non-Approved Substances, and is prohibited at all times. It is prohibited at all times for athletes subject to WADA jurisdiction. BPC-157 supplied by Ascend Peptides UK is for in-vitro laboratory research only and is not represented as a substance for use by athletes or in any human or veterinary application.

What is the MHRA status of BPC-157 in the UK?

BPC-157 is not licensed as a medicinal product under the UK Human Medicines Regulations 2012. It is supplied strictly for in-vitro laboratory research. The Medicines and Healthcare products Regulatory Agency (MHRA) is the relevant medicines regulator in the UK post Brexit (following the UK’s post-Brexit separation from the European Union regulatory framework ). Ascend Peptides UK supplies BPC-157 for in-vitro laboratory research only, not for human or veterinary use. A research-use-only label is not in itself a legal classification; whether a product is regulated as a medicine depends on how it is presented and what it is intended for.

How should BPC-157 be stored?

Storage conditions for BPC-157 are being confirmed with the manufacturer; the current position is shown on the BPC-157 product page. Ascend Peptides UK does not publish reconstitution or in-use instructions. General background is in the peptide storage guide.

How much does BPC-157 cost from Ascend Peptides UK?

Current prices for BPC-157 10mg and its bundles (the Regenesis Complex with TB-500, and the Tri Regenerative Complex adding GHK-CU) are shown on each product page. All orders of £75 or more qualify for a free 10ml bacteriostatic water.

Order BPC-157 from Ascend Peptides UK: Same Working-Day Dispatch on In-Stock Orders

Browse the BPC-157 10mg product page for the published Janoshik certificate for a tested batch and UK dispatch information. For combined recovery research protocols, the Regenesis Complex bundle (BPC-157 plus TB-500) and the Tri Regenerative Complex bundle (BPC-157 plus TB-500 plus GHK-CU) are available at a bundle price. For the complete recovery research category framework, see the recovery research peptides UK page, or start with the main research peptides in the UK hub for the complete supplier model.

RESEARCH USE ONLY

All products supplied by Ascend Peptides UK are intended strictly for in-vitro laboratory research purposes only. BPC-157 is not a licensed medicinal product under the UK Human Medicines Regulations 2012 and is not for human or veterinary use. No dosing or administration guidelines are provided. Products are supplied to qualified research professionals only.

📥  FREE DOWNLOAD

For research professionals only — instant download, no payment required